Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000670079 | SCV000794895 | likely pathogenic | Wilson disease | 2017-10-18 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000670079 | SCV001201648 | pathogenic | Wilson disease | 2023-12-13 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 850 of the ATP7B protein (p.Thr850Ile). This variant is present in population databases (rs777629392, gnomAD 0.01%). This missense change has been observed in individual(s) with Wilson disease (PMID: 21034864, 27398169, 29321352). ClinVar contains an entry for this variant (Variation ID: 554444). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ATP7B protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. |
Mayo Clinic Laboratories, |
RCV001509442 | SCV001716164 | likely pathogenic | not provided | 2022-10-21 | criteria provided, single submitter | clinical testing | PP3, PP4, PM2, PS4_moderate |
Fulgent Genetics, |
RCV000670079 | SCV002799405 | pathogenic | Wilson disease | 2022-02-16 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000670079 | SCV004216408 | likely pathogenic | Wilson disease | 2024-01-25 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000670079 | SCV002087843 | pathogenic | Wilson disease | 2021-06-28 | no assertion criteria provided | clinical testing |